2014 Breast Cancer Research Partnership

Professor Parry Guilford
University of Otago
Funder(s): HRC, Breast Cancer Cure, The New Zealand Breast Cancer Foundation
Synthetic lethal targeting of lobular breast cancer
$199,792
24 months

Lay summary

The inactivation of tumour suppressor genes is the most common of all genetic events in cancer but not one that can be targeted by conventional therapy, because the tumour suppressor protein is lost from the cancer cell. However, the loss of these genes is predicted to create vulnerabilities in the cancer cell that can nevertheless be targeted with drugs. We have compelling data showing that the loss the the tumour suppressor gene CDH1, an event that is a hallmark of the lobular subtype of breast cancer, creates vulnerabilities which can be targeted with drugs. In this project we will develop new breast cancer treatments which exploit these vulnerabilities.

Back to Funding Recipients